Peter Danenberg
Overview
Explore the profile of Peter Danenberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
147
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Raez L, Danenberg K, Sumarriva D, Usher J, Sands J, Castrellon A, et al.
Cancer Drug Resist
. 2022 May;
4(4):1061-1071.
PMID: 35582387
We report an exploratory analysis of cfRNA as a biomarker to monitor clinical responses in non-small cell lung cancer (NSCLC), breast cancer, and colorectal cancer (CRC). An analysis of cfRNA...
2.
Link K, Kornmann M, Staib L, Kreuser E, Gaus W, Rottinger E, et al.
World J Gastrointest Surg
. 2022 Jan;
13(12):1597-1614.
PMID: 35070066
Rarely, scientific developments centered around the patient as a whole are published. Our multidisciplinary group, headed by gastrointestinal surgeons, applied this research philosophy considering the most important aspects of the...
3.
Hodara E, Morrison G, Cunha A, Zainfeld D, Xu T, Xu Y, et al.
JCI Insight
. 2019 Feb;
4(5).
PMID: 30702443
Molecular profiling of prostate cancer with liquid biopsies, such as circulating tumor cells (CTCs) and cell-free nucleic acid analysis, yields informative yet distinct data sets. Additional insights may be gained...
4.
Ishiba T, Nakagawa T, Sato T, Nagahara M, Oda G, Sugimoto H, et al.
Springerplus
. 2016 Jan;
4:817.
PMID: 26722637
Neoadjuvant chemotherapy (NAC) has become a standard therapy for patients with advanced breast cancer. Pathological complete response (pCR) after NAC is an important prognostic indicator, but some patients with pCR...
5.
Kornmann M, Hebart H, Danenberg K, Goeb R, Staib L, Kron M, et al.
Eur J Cancer
. 2011 Dec;
48(10):1443-51.
PMID: 22133572
Background: Molecular markers to predict response to 5-fluorouracil (FU)-based treatment of recurrent or metastasised colorectal cancer (mCRC) are not established. The aim of this trial was to determine the value...
6.
Jensen L, Kuramochi H, Cruger D, Lindebjerg J, Kolvraa S, Danenberg P, et al.
Tumour Biol
. 2011 Jul;
32(5):977-83.
PMID: 21732224
Microsatellite instability (MSI) is caused by defective mismatch repair (MMR) and is one of the very few molecular markers with proven clinical importance in colorectal cancer with respect to heredity,...
7.
Grimminger P, Danenberg P, Dellas K, Arnold D, Rodel C, Machiels J, et al.
Clin Cancer Res
. 2011 May;
17(10):3469-77.
PMID: 21558395
Purpose: Phase II trials in locally advanced rectal cancer have shown that cetuximab-based neoadjuvant radiochemotherapy is feasible but without an improvement in complete pathologic response rates. Our goal was to...
8.
Oh D, DeMeester S, Dunst C, Mori R, Lehman B, Kuramochi H, et al.
Surg Endosc
. 2008 Sep;
23(6):1346-52.
PMID: 18813976
Background: A rodent model of gastroduodenal-esophageal reflux can result in replacement of squamous esophageal mucosa with intestinal-type columnar mucosa and carcinoma. The validity of this model is debated, as it...
9.
Banki F, Yacoub W, Hagen J, Mason R, Ayazi S, DeMeester S, et al.
J Am Coll Surg
. 2008 Jul;
207(1):30-5.
PMID: 18589358
Background: Carcinoembryonic antigen (CEA) and plasma DNA are known to be elevated in patients with esophageal cancer and are higher in patients with disseminated disease. The sensitivity and specificity of...
10.
Artinyan A, Essani R, Lake J, Kaiser A, Vukasin P, Danenberg P, et al.
J Gastrointest Surg
. 2005 Dec;
9(9):1216-21.
PMID: 16332476
TNM staging in colon cancer has several limitations. Prognostic molecular markers are now being developed to address these limitations. The aim of this study was to identify a combination of...